Stephen Mok

4.6k total citations · 2 hit papers
29 papers, 2.6k citations indexed

About

Stephen Mok is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Stephen Mok has authored 29 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 18 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Stephen Mok's work include Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (11 papers) and Melanoma and MAPK Pathways (8 papers). Stephen Mok is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (11 papers) and Melanoma and MAPK Pathways (8 papers). Stephen Mok collaborates with scholars based in United States, Singapore and Denmark. Stephen Mok's co-authors include Antoni Ribas, Richard C. Koya, Thomas G. Graeber, Lídia Robert, Brian L. West, Gideon Bollag, Jingying Xu, Lily Wu, Begoña Comı́n-Anduix and Jennifer Tsoi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Stephen Mok

29 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer

2013 467 citations Jingying Xu, Jemima Escamilla et al. Cancer Research profile →
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF ^V600E melanoma

2015 435 citations Siwen Hu‐Lieskovan, Stephen Mok et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen Mok United States	15	1.9k	1.5k	873	248	161	29	2.6k
Maria Jure–Kunkel United States	21	2.3k 1.2×	2.0k 1.4×	498 0.6×	379 1.5×	199 1.2×	42	3.0k
Vikram R. Juneja United States	13	1.4k 0.7×	1.4k 1.0×	947 1.1×	271 1.1×	64 0.4×	19	2.6k
Malin Pedersen United Kingdom	22	1.1k 0.6×	673 0.5×	1.3k 1.4×	267 1.1×	126 0.8×	37	2.4k
Hong-Fen Guo United States	25	1.1k 0.6×	608 0.4×	783 0.9×	146 0.6×	551 3.4×	50	2.0k
Patricia Van Belle United States	16	1.1k 0.6×	383 0.3×	1.4k 1.6×	109 0.4×	140 0.9×	22	2.1k
Matthew Kraman United Kingdom	14	2.5k 1.3×	1.5k 1.1×	1.1k 1.3×	251 1.0×	114 0.7×	21	3.5k
Jack F. Shern United States	23	2.1k 1.1×	733 0.5×	1.5k 1.7×	431 1.7×	72 0.4×	53	3.4k
Michael A. Cannarile Switzerland	16	770 0.4×	1.3k 0.9×	435 0.5×	183 0.7×	52 0.3×	27	1.9k
Max Jan United States	14	1.1k 0.6×	1.4k 0.9×	1.0k 1.2×	58 0.2×	121 0.8×	28	2.9k
James O. Jones United Kingdom	9	2.3k 1.2×	1.3k 0.9×	842 1.0×	222 0.9×	73 0.5×	18	3.0k

Countries citing papers authored by Stephen Mok

Since Specialization

Citations

This map shows the geographic impact of Stephen Mok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Mok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Mok more than expected).

Fields of papers citing papers by Stephen Mok

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Mok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Mok. The network helps show where Stephen Mok may publish in the future.

Co-authorship network of co-authors of Stephen Mok

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Mok. A scholar is included among the top collaborators of Stephen Mok based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Mok. Stephen Mok is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mok, Stephen, Colm R. Duffy, & James P. Allison. (2018). Effects of anti-CTLA-4 and anti-PD-1 on memory T-cell differentiation and resistance to tumor relapse. The Journal of Immunology. 200(Supplement_1). 122.2–122.2. 1 indexed citations

Mok, Stephen, Colm R. Duffy, & James P. Allison. (2017). Abstract 1685: Effects of anti-ctla-4 and anti-pd-1 on memory T-cell differentiation and resistance to tumor relapse. Cancer Research. 77(13_Supplement). 1685–1685. 2 indexed citations

Tavaré, Richard, Helena Escuin-Ordinas, Stephen Mok, et al.. (2015). An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Research. 76(1). 73–82. 237 indexed citations

Hu‐Lieskovan, Siwen, Stephen Mok, Blanca Homet Moreno, et al.. (2015). Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF ^V600E melanoma. Science Translational Medicine. 7(279). 279ra41–279ra41. 435 indexed citations breakdown →

Mok, Stephen, Jennifer Tsoi, Richard C. Koya, et al.. (2015). Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition. BMC Cancer. 15(1). 356–356. 47 indexed citations

Moreno, Blanca Homet, Stephen Mok, Begonya Comin-Anduix, Siwen Hu‐Lieskovan, & Antoni Ribas. (2015). Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. OncoImmunology. 5(7). e1052212–e1052212. 82 indexed citations

Robert, Lídia, Jennifer Tsoi, Xiaoyan Wang, et al.. (2014). CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire. Clinical Cancer Research. 20(9). 2424–2432. 280 indexed citations

Robert, Lídia, Christina L. Harview, Ryan Emerson, et al.. (2014). Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. OncoImmunology. 3(6). e29244–e29244. 66 indexed citations

Robert, Lídia, Christina L. Harview, Ryan Emerson, et al.. (2014). Abstract 5015: TCR usage analysis in blood reveals different mechanisms of action of CTLA-4 and PD-1 blockade in patients. Cancer Research. 74(19_Supplement). 5015–5015. 1 indexed citations

10.

Mok, Stephen, Richard C. Koya, Christopher Tsui, et al.. (2013). Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy. Cancer Research. 74(1). 153–161. 252 indexed citations

11.

Xu, Jingying, Jemima Escamilla, Stephen Mok, et al.. (2013). CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer. Cancer Research. 73(9). 2782–2794. 467 indexed citations breakdown →

12.

Knight, Deborah A., Shin Foong Ngiow, Ming Li, et al.. (2013). Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. Journal of Clinical Investigation. 123(7). 3182–3182. 4 indexed citations

13.

Koya, Richard C., Stephen Mok, Nicholas Otte, et al.. (2012). BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy. Cancer Research. 72(16). 3928–3937. 187 indexed citations

14.

Wong, Nyuk Hien, et al.. (2012). Performance Evaluation of Solar Chimney System in the Tropics. National University of Singapore. 22. 299–305. 1 indexed citations

15.

Euw, Erika von, Mohammad Atefi, Narsis Attar, et al.. (2012). Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Molecular Cancer. 11(1). 22–22. 61 indexed citations

16.

Huang, Rong, Jason Jalil, James S. Economou, et al.. (2011). CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans. Clinical Cancer Research. 17(12). 4101–4109. 120 indexed citations

17.

Koya, Richard C., Stephen Mok, Begoña Comı́n-Anduix, et al.. (2010). Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proceedings of the National Academy of Sciences. 107(32). 14286–14291. 48 indexed citations

18.

Søndergaard, Jonas Nørskov, Ramin Nazarian, Qi Wang, et al.. (2010). Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032. Journal of Translational Medicine. 8(1). 171 indexed citations

19.

Vo, Dan D., Robert M. Prins, Jonathan L. Begley, et al.. (2009). Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824. Cancer Research. 69(22). 8693–8699. 119 indexed citations

20.

Begley, Jonathan L., Dan D. Vo, Lilah F. Morris, et al.. (2008). Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunology Immunotherapy. 58(5). 699–708. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact